Most excitingly, [18F]AV-1451 has just been announced to meet its two primary endpoints, defined as predicting brain tau pathology and predicting Alzheimer’s disease diagnosis, in a phase III study (A16 trial). Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.